Your browser doesn't support javascript.
loading
The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis.
Pappa, Georgia; Sgouros, Dimitrios; Theodoropoulos, Konstantinos; Kanelleas, Antonios; Bozi, Evangelia; Gregoriou, Stamatios; Krasagakis, Konstantinos; Katoulis, Alexander C.
Afiliação
  • Pappa G; 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Sgouros D; 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Theodoropoulos K; 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Kanelleas A; 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Bozi E; 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Gregoriou S; 1st Department of Dermatology and Venereology, "Andreas Suggros" Hospital, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece.
  • Krasagakis K; Department of Dermatology, University General Hospital of Heraklion, 71500 Heraklion, Greece.
  • Katoulis AC; 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
J Clin Med ; 11(19)2022 Sep 24.
Article em En | MEDLINE | ID: mdl-36233501
ABSTRACT
Atopic dermatitis (AD) is a common inflammatory skin disease with a complex pathophysiology, intertwining immune dysregulation, epidermal barrier dysfunction, IgE sensitization, environmental factors and genetic predisposition. It has been recently identified that interleukins -4 and -13 play crucial roles in the type-2-driven inflammation that characterizes AD, contributing to its symptomatology. Novel therapeutic approaches that target Th2 cytokines and their respective pathways have been developed, aiming to optimize the treatment of AD.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article